Hepatitis C virus: A critical approach to who really needs treatment

Voumvouraki, Argyro

doi:10.4254/wjh.v14.i1.1

Cited by 8 publications

(4 citation statements)

References 414 publications

(401 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, primary liver cancer and alcohol were the most significant causes of death in HCV patients who achieved SVR, while high alcohol consumption was associated with an increased rate of HCC occurrence or recurrence after the achievement of SVR with DAAs treatment [5,27,28,[166][167][168] . This observation was confirmed [169] .…”

Section: The Role Of Alcoholsupporting

confidence: 69%

Hepatocellular carcinoma after treatment of hepatitis C with direct-acting antivirals: a critical re-appraisal

Tsomidis¹,

Voumvouraki²

2023

Hepatoma Res

View full text Add to dashboard Cite

Soon after introducing direct-acting antiviral agents (DAAs) for chronic hepatitis C treatment, there began a debate over the possibility of hepatocellular carcinoma (HCC) after viral clearance. Although several reports suggested that the question has been answered negatively, other reports suggested the opposite. The present review presents data in favor and against the null hypothesis and analyzes the scientific background of the possible participation of DAAs in HCC development. The reasons for the discrepancy among studies are presented. These include heterogeneity of patient selection, the nature of the studies, and the tumors themselves are responsible for varying results. Exogenous factors like alcohol consumption or metabolic syndrome confound these findings and suggest the need for statistical adjustments. The need for careful attention to the statistical details is exemplified, and the significant points of almost universal agreements are identified. The conclusion is that the definitive study is impossible for ethical and scientific reasons, and the physician should not ignore even simple personal observations and screening of all patients with extensive fibrosis in HCC, irrespective of sustained virologic response, until a robust, reliable prognostic model can be invented.

show abstract

Section: The Role Of Alcoholsupporting

confidence: 69%

Hepatocellular carcinoma after treatment of hepatitis C with direct-acting antivirals: a critical re-appraisal

Tsomidis¹,

Voumvouraki²

2023

Hepatoma Res

View full text Add to dashboard Cite

show abstract

“…Oral tablet regimes achieve very high curing rates and novel drug loaded β-cyclodextrin NPs may even improve the safety and tolerability of treatments [52]. Accordingly, the World Health Organization is confident that hepatitis C may one day be eradicated [53]. In contrast, there is a risk of hepatitis B reactivation even in cured patients [54].…”

Section: Viral Hepatitismentioning

confidence: 99%

Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications

Kaps,

Limeres,

Schneider

et al. 2023

IJMS

View full text Add to dashboard Cite

Hepatocytes exert pivotal roles in metabolism, protein synthesis and detoxification. Non-parenchymal liver cells (NPCs), largely comprising macrophages, dendritic cells, hepatic stellate cells and liver sinusoidal cells (LSECs), serve to induce immunological tolerance. Therefore, the liver is an important target for therapeutic approaches, in case of both (inflammatory) metabolic diseases and immunological disorders. This review aims to summarize current preclinical nanodrug-based approaches for the treatment of liver disorders. So far, nano-vaccines that aim to induce hepatitis virus-specific immune responses and nanoformulated adjuvants to overcome the default tolerogenic state of liver NPCs for the treatment of chronic hepatitis have been tested. Moreover, liver cancer may be treated using nanodrugs which specifically target and kill tumor cells. Alternatively, nanodrugs may target and reprogram or deplete immunosuppressive cells of the tumor microenvironment, such as tumor-associated macrophages. Here, combination therapies have been demonstrated to yield synergistic effects. In the case of autoimmune hepatitis and other inflammatory liver diseases, anti-inflammatory agents can be encapsulated into nanoparticles to dampen inflammatory processes specifically in the liver. Finally, the tolerance-promoting activity especially of LSECs has been exploited to induce antigen-specific tolerance for the treatment of allergic and autoimmune diseases.

show abstract

“… 5 Furthermore, intravenous drug users are at relatively high risk of contracting hepatitis C, and those who have been previously infected with this disease but have not been cured account for the majority of existing patients. 6 China is a high epidemic area for viral hepatitis. Viral hepatitis is the most common cause of clinically abnormal liver function, and the resulting mortality has remained high among China’s notifiable infectious diseases.…”

Section: Introductionmentioning

confidence: 99%

The Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study

Shi,

Yang,

et al. 2024

JMDH

View full text Add to dashboard Cite

To analyse clinical manifestations of unexplained abnormal liver function and perform hepatobiliary histopathology procedures on patients to evaluate the value of liver biopsy in diagnosing the aetiology of unexplained abnormal liver function. Methods: A convenience sampling method was used to retrospectively collect the data of patients who were diagnosed with unexplained abnormal liver function and who received liver biopsy in the Pathology Department of Tianjin Second People's Hospital, China, between March 2022 and July 2023 to analyse liver pathology and clinical manifestations. Results: A total of 1302 patients were included in this study, which mainly included 11 diseases: autoimmune liver disease (74 cases, 5.68%), drug-induced liver injury (DILI) (204 cases, 15.67%), cancer (237 cases, 18.20%), non-alcoholic fatty liver disease (104 cases, 7.99%), non-alcoholic steatohepatitis (74 cases, 5.68%), viral hepatitis (490 cases, 37.63%), other types of hepatitis (30 cases, 2.30%), cholestatic liver disease (17 cases, 1.31%), alcoholic liver disease (15 cases, 1.15%), hepatic cyst (5 cases, 0.38%) and Gilbert syndrome (4 cases, 0.31%). The success rate of liver biopsy sampling was 100%, and (1.52 ± 0.130) tissue strips were sampled. The average operating time was 11.52 minutes. The percutaneous liver biopsy did not significantly increase short-term liver function index values (serum γ-glutamyl transpeptidase, total bilirubin, alanine transaminase, aspartate aminotransferase, alkaline phosphatase). Ninety-two patients had a small amount of liver subcapsular fluid, but there was no progress after medical treatment. Conclusion: Ultrasound-guided percutaneous liver biopsy has value in the diagnosis of unexplained abnormal liver function. Viral hepatitis, cancer and DILI are the most common causes of unexplained abnormal liver function. Liver biopsy does not aggravate the organic and functional impairment of the liver.

show abstract

Hepatitis C virus: A critical approach to who really needs treatment

Cited by 8 publications

References 414 publications

Hepatocellular carcinoma after treatment of hepatitis C with direct-acting antivirals: a critical re-appraisal

Hepatocellular carcinoma after treatment of hepatitis C with direct-acting antivirals: a critical re-appraisal

Liver Cell Type-Specific Targeting by Nanoformulations for Therapeutic Applications

The Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study

Contact Info

Product

Resources

About